4-{3-[3-{4-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-butoxy}-4-(4-methyl-benzyloxy)-benzoyl]-indol-1-yl}-butyric acid

ID: ALA289613

Chembl Id: CHEMBL289613

PubChem CID: 19085571

Max Phase: Preclinical

Molecular Formula: C42H47N3O6

Molecular Weight: 689.85

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccccc1N1CCN(CCCCOc2cc(C(=O)c3cn(CCCC(=O)O)c4ccccc34)ccc2OCc2ccc(C)cc2)CC1

Standard InChI:  InChI=1S/C42H47N3O6/c1-31-15-17-32(18-16-31)30-51-39-20-19-33(42(48)35-29-45(22-9-14-41(46)47)36-11-4-3-10-34(35)36)28-40(39)50-27-8-7-21-43-23-25-44(26-24-43)37-12-5-6-13-38(37)49-2/h3-6,10-13,15-20,28-29H,7-9,14,21-27,30H2,1-2H3,(H,46,47)

Standard InChI Key:  JJRGSYIIOKDBJX-UHFFFAOYSA-N

Associated Targets(non-human)

Srd5a1 Steroid 5-alpha-reductase (312 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 689.85Molecular Weight (Monoisotopic): 689.3465AlogP: 7.61#Rotatable Bonds: 17
Polar Surface Area: 93.47Molecular Species: ACIDHBA: 8HBD: 1
#RO5 Violations: 2HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.83CX Basic pKa: 7.32CX LogP: 5.18CX LogD: 4.92
Aromatic Rings: 5Heavy Atoms: 51QED Weighted: 0.08Np Likeness Score: -1.00

References

1. Sato H, Kitagawa O, Aida Y, Chikazawa J, Kurimoto T, Takei M, Fukuta Y, Yoshida K..  (1999)  Dual-acting agents with alpha1-adrenoceptor antagonistic and steroid 5alpha-reductase inhibitory activities. Synthesis and evaluation of arylpiperazine derivatives.,  (11): [PMID:10386934] [10.1016/s0960-894x(99)00230-9]

Source